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Background: We investigated the efﬁcacy of everolimus against nonclear-cell renal cell carcinoma (nccRCC).
Patients and methods: Patients with nccRCC received 10-mg everolimus once daily until disease progression or
unacceptable toxicity. Patients who had received a VEGF- tyrosine kinase inhibitor (TKI) previously were included.
Results: A total of 49 patients were enrolled. Twenty-three patients (46.9%) received prior anti-VEGF agents. A partial
response was observed in ﬁve patients (10.2%) and stable disease in 25 patients (51.0%). The disease progressed in
16 patients (32.7%) despite the administration of everolimus. Two of the ﬁve patients who showed an objective
response to everolimus had chromophobe carcinoma, whereas two had papillary carcinoma and one had unclassiﬁable
carcinoma. Thirty-six patients experienced disease progression during follow-up, and the median progression-free
survival (PFS) was 5.2 months. Chromophobe RCC patients seemed to have longer PFS than nccRCC patients with
the other histological subtypes (P = 0.084). Previous VEGF-TKI treatment did not inﬂuence the efﬁcacy of everolimus,
and the toxicity proﬁles were in line with previous reports.
Conclusion: Everolimus shows certain efﬁcacy against nccRCC, particularly in patients with chromophobe RCC, and
prior treatment with a VEGF-TKI appears not inﬂuencing the outcome of everolimus therapy in nccRCC patients.
ClinicalTrials.gov number: NCT00830895.
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introduction
More than 10 000 patients died of renal cell carcinoma (RCC)
in the United States in 2011 [1]. In Korea, more than 2500
patients develop RCC annually, and more than 1000 patients
died of RCC in 2010 (http://www.cancer.go.kr/ncic/cics_f/02/
022/index.html). RCC is the most common primary renal
neoplasm, accounting for 80%–85% of primary renal
neoplasm. RCC is composed of distinct subtypes designated
clear cell (70%–80%), papillary (10%–20%), chromophobe
(5%), collecting duct (<5%), medullary (<5%), and
unclassiﬁable (∼5%) [2, 3]. Clear-cell RCC (ccRCC) has
provided the paradigm for translational research [4]. RCC is
characterized by inactivation of the von Hippel–Lindau gene,
which causes activation of the downstream effectors
mammalian target of rapamycin (mTOR) and vascular
endothelial growth factor (VEGF). Targeting the downstream
effectors VEGF and mTOR with sunitinib (VEGF) [5],
sorafenib (VEGF) [6], temsirolimus (mTOR), and everolimus
(mTOR) [7] may provide effective treatment. Since the
approval of these targeted agents, systemic management of
advanced and metastatic RCC has improved over the past 5
years [4, 8].
Most trials testing these drugs excluded or under-
represented nonclear-cell histology [5, 6, 9]. Hence, most data
regarding the efﬁcacy of sunitinib and sorafenib in nonclear-
cell RCC (nccRCC) have come from the expanded access
program of sorafenib and sunitinib. However, the Global
Advanced Renal Cell Carcinoma (ARCC) trial that tested the
efﬁcacy of temsirolimus against RCC included a substantial
number of patients with nccRCC (∼20%) and showed
considerable efﬁcacy of temsirolimus in nccRCC patients
(median progression-free survival [PFS], 7.0 months) [7].
However, the ARCC study did not include a central pathology
review, and subclassiﬁcation of nccRCC was not provided [4].
Hence, the appropriate treatment of metastatic nccRCC
remains unclear.
A phase III trial (RECORD-1) of everolimus showed
promising efﬁcacy in ccRCC patients whose disease progressed
while on sorafenib or sunitinib [10]. And RAD001 Expanded
Access Clinical Trial in RCC (REACT) demonstrated an
objective response rate (ORR) of 1.3% and a median PFS of
12.14 weeks in nccRCC patients [11]. However, there was not a
single trial evaluating the efﬁcacy of everolimus mainly in
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nccRCC patients. Considering the similar mechanisms of
action of temsirolimus and everolimus, we hypothesized that
everolimus would show a clinical beneﬁt in nccRCC patients.
Here, we examined the clinical efﬁcacy of everolimus in
nccRCC patients. First, we evaluated the exact ORR to
everolimus and the PFS after everolimus administration in
nccRCC patients. To analyze the clinical beneﬁt of everolimus
according to nccRCC subtype, we enrolled patients with all
subtypes of nccRCC. Furthermore, we investigated the impact
of previous anti-VEGF treatment on the clinical efﬁcacy of
subsequent mTOR inhibitor treatment.
materials and methods
study design and patient eligibility
We conducted the study at ﬁve centers in Korea. This open-label, single-
arm, multicenter phase II study was conducted in accordance with the
Declaration of Helsinki and was consistent with both the International
Conference on Harmonization Good Clinical Practice and the applicable
regulatory requirements. Written informed consent was obtained from all
patients. The study protocol was reviewed and approved by the institutional
review board of each participating hospital.
The entry criteria included pathologically proven nccRCC with a
metastatic lesion, age >18 years, Eastern Cooperative Oncology Group
(ECOG) performance scale (PS) 0–2, adequate renal (creatinine clearance
≥30 ml/min), cardiac, and hepatic [total bilirubin ≤1.5× upper limit
normal (ULN)], AST, ALT ≤2.5× ULN, and alkaline phosphatase ≤2.5×
ULN) function. Patients with the following RCC subtypes were eligible:
papillary, chromophobe, collecting duct, sarcomatoid, oncocytic, and
unclassiﬁable. Furthermore, patients who received previous anti-VEGF
therapy were eligible.
Patients were deemed ineligible if they had previous treatment with an
mTOR inhibitor, clinically uncontrolled central nervous system metastasis,
interstitial pulmonary disease, QTc interval prolongation (QTc >450 ms for
males and >470 ms for females), or other serious diseases or medical
conditions (e.g. unstable heart disease despite treatment or a history of
myocardial infarction within 6 months before the study).
treatment plan
After providing informed consent, patients received everolimus 10 mg/day
orally. Four weeks was designated as one cycle. Doses were delayed or
reduced to 5 mg/day based on the relevant hematological and
nonhematological toxic effects according to National Cancer Institute-
Common Terminology Criteria of Adverse Events (version 3.0) criteria.
Treatment was continued until disease progression, death, unacceptable
toxicity, or the withdrawal of consent.
study end points
The primary end point was PFS. Secondary end points included ORR, toxic
effects, and overall survival (OS). Responses were classiﬁed as complete
response (CR), partial response (PR), stable disease (SD), or progressive
disease (PD) according to the RECIST version 1.0 [12]. PFS was calculated
as the time from study enrollment to documentation of disease progression
or death from any cause, and OS was calculated as the time from study
enrollment to death from any cause.
evaluation
Baseline patient evaluation included medical history, physical examination,
PS, and laboratory measurements including a complete blood count, renal
function tests, and hepatic function tests. Tumor measurements (assessed
by computed tomography) were carried out at screening and repeated
every 8 weeks throughout the study. Tumor measurements were carried out
upon discontinuation of the study drug. During the study, we monitored
adverse events, PS, and blood chemistry tests.
statistical analysis
This study was designed to achieve a PFS ≥6 months with an α-error of
10% and a β-error of 10%. Assuming 18 months of accrual and 6 months
of follow-up with an α-error of 10% and a β-error of 10%, 48 patients were
required.
As there were limited source data on nccRCC to determine the PFS in
the null hypothesis, the following method was used. Because Patard et al.
suggested OS does not differ between ccRCC and nccRCC [13], we used
ccRCC data to assume a PFS of 4 months. As our inclusion and exclusion
criteria did not set limitations regarding previous treatment, we assumed a
ratio of previously treated to treatment-naïve patients of 1 : 1. Based on the
results of the phase III trial of everolimus, we assumed PFS of 3.0 months
for previously treated patients [10]. Alternatively, based on the phase III
trials of sunitinib [5] and bevacizumab [14], we assumed PFS of 5.0
months for treatment-naïve patients. Therefore, based on a 1 : 1 ratio of
previously treated to treatment-naïve patients, we assumed PFS of 4
months in our null hypothesis.
Statistical analyses of 2 × 2 contingency tables were carried out using
Pearson’s χ2 test or Fisher’s exact test, as appropriate. The Kaplan–Meier
method was used to calculate PFS and OS. Comparisons between groups
were made by log-rank tests. The impact of continuous variables on clinical
outcomes was calculated with logistic regression and a Cox regression
model. A multivariate analysis was carried out with a logistic regression
model for response and Cox regression models for PFS and OS. All
statistical tests were two sided with signiﬁcance deﬁned as P < 0.05. All
analyses were carried out with SPSS for Windows Version 12.0 (IBM,
Chicago, IL).
results
patient characteristics
Forty-nine Korean patients from ﬁve centers were enrolled
from January 2009–July 2011. Median patient age was 57.0
years (range: 23.8–75.5 years), and the male : female ratio was
37 : 12. Based on histology, 29 patients had papillary RCC, 8
had chromophobe RCC, 6 had unclassiﬁable RCC, 4 had
sarcomatoid RCC, and 2 had collecting duct RCC. Twenty-
three patients (46.9%) received prior anti-VEGF agents
(sunitinib or sorafenib). When patients were categorized by
International mRCC DB Consortium risk groups [15], 3
patients (6.1%) were found to have favorable risk disease, 34
(69.4%) had intermediate risk disease, and 10 (20.4%) had
poor risk disease (Table 1).
efﬁcacy
Of the 49 patients, ﬁve achieved conﬁrmed PR (10.2%),
whereas 25 patients had SD (25%). Disease progression
occurred regardless of everolimus administration in 16 patients
(32.7%). Three patients were unable to undergo tumor
assessment: one due to toxicity and two due to the withdrawal
of consent before completion of the ﬁrst cycle of everolimus
treatment. Of the ﬁve patients who achieved PR, two had
papillary RCC, two had chromophobe RCC, and one had
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unclassiﬁable RCC (Table 2). Figure 1 shows the maximum
reduction in tumor size for the 30 patients who achieved at
least SD.
The ORR did not differ according to tumor histology
(P = 0.670), previous immunotherapy (P = 0.730), previous
anti-VEGF treatment (P = 0.293), or previous nephrectomy
(P = 0.602) (Table 3).
During a median follow-up of 19.1 months (range: 1.4–36.1
months), 36 patients experienced disease progression, and 30
patients died. Median PFS of the study patients was 5.2
months (Figure 2A). Patients with chromophobe RCC tended
to have longer PFS than those with the other RCC subtypes
(P = 0.084, 13.1 versus 3.4 months) (Figure 2B). Previous anti-
VEGF treatment did not signiﬁcantly inﬂuence PFS (5.3
months in patients with previous anti-VEGF treatment versus
3.7 months in those without, P = 0.110, Figure 2C). Further,
previous immunotherapy (P = 0.804) and previous
nephrectomy (P = 0.773) also were not correlated with PFS. PS
(P = 0.275), gender (P = 0.909), and age (P = 0.054) were not
related to PFS. Risk stratiﬁcation did not have predictive value
in terms of PFS in these patients (P = 0.902) (Figure 2D).
Interestingly, the duration from initial diagnosis to everolimus
administration was predictive of PFS (i.e. patients who did not
receive everolimus until 1 year after diagnosis had longer PFS
than patients who received everolimus within the ﬁrst year
after diagnosis [7.1 versus 2.8 months P = 0.005])
(supplementary ﬁle 1A, available at Annals of Oncology
online). Upon disease progression while receiving everolimus,
10 patients received anti-VEGF treatment, 4 received
temsirolimus, and 8 received immunotherapy.
The median OS of the study patients was 14.0 months
(Figure 2E), and OS did not differ according to tumor
histology (P = 0.393) (Figure 2F). Prior treatment with an anti-
VEGF agent (P = 0.740) (Figure 2G), immunotherapy
(P = 0.586), or nephrectomy (P = 0.727) did not inﬂuence OS.
Age (P = 0.665), gender (P = 0.476), and PS (P = 0.311) were
not correlated with OS, and risk stratiﬁcation did not have
prognostic value for OS (P = 0.828) (Figure 2H). In contrast to
its prognostic relationship with PFS, the duration from initial
diagnosis to everolimus treatment was not predictive of OS
(P = 0.212) (supplementary ﬁle 1B, available at Annals of
Oncology online).
When patients with collecting duct carcinoma and
sarcomatoid carcinoma were excluded and efﬁcacy analysis was
carried out on the remaining 43 patients, ORR was 11.6% and
PFS was 5.3 months. Median OS for these 43 patients was 12.7
months, and ORR, PFS, and OS are summarized according to
tumor histology in Table 4.
drug exposure and safety
During the study period, 288 cycles (range: 1–22 cycles) were
given to the study patients. Dose reduction was carried out in 8
patients (16.3%), and dose delay in 10 patients (20.4%).
Overall, 33 patients (67.3%) received full-dose intensity
Table 1. Baseline characteristics of the 49 patients in the study
Characteristics Number (%) Median (Range)
Sex (M/F) 37/12
Age, years (median) 57.0 (23.7–75.5)
ECOG performance scale
0 8 (16.3)
1 37 (75.5)
2 4 (8.2)
Histology
Papillary 29 (59.2)
Chromophobe 8 (16.3)
Collecting duct 2 (4.1)
Sarcomatoid 4 (8.2)
Unclassiﬁable 6 (12.2)
Nephrectomy
Yes 35 (71.4)
No 14 (28.6)
Prior treatment
Immunotherapy 5 (10.2)
Sunitinib 21 (42.9)
Sorafenib 6 (12.2)
Anti-VEGF (either sunitinib or sorafenib) 23 (46.9)
Time from diagnosis to everolimus
<1 year 28 (57.1)
≥1 year 21 (42.9)
International mRCC DB Consortium risk group
Favorable 3 (6.1)
Intermediate 34 (69.4)
Poor 10 (20.4)
Unknown 2 (4.1)
ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial
growth factor; mRCC DB, Metastatic Renal Cell Carcinoma Database.
Table 2. Characteristics of the ﬁve patients who achieved an objective tumor response to everolimus
ID Sex Age at diagnosis
(years)
Age at Study
(years)
Pathology ImmunoTx Anti-VEGF Nephrectomy Risk group* PFS (months) PD
1 Female 55.9 56.1 Chromophobe 0 0 1 Intermediate 3.8 No
2 Male 63.7 65.2 Papillary 0 0 1 Intermediate 5.2 Yes
3 Male 69.7 70.2 Unclassiﬁable# 0 0 1 Intermediate 10.6 No
4 Male 50.1 51.9 Papillary 1 0 1 Poor 5.3 Yes
5 Male 38.6 40.4 Chromophobe 0 1 0 Intermediate 9.1 No
*Risk group based on the International Metastatic Renal Cell Carcinoma Database Consortium risk groups.
#The patient (ID 3) with unclassiﬁable RCC had an Xp11.2 translocation.
ImmunoTx, immunotherapy; VEGF, vascular endothelial growth factor; PFS, progression-free survival; PD, progressive disease.
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treatment. The causes for dose delay or dose reduction
included hematologic adverse events (N = 4), pneumonitis
(N = 2), stomatitis (N = 2), hyperglycemia (N = 1),
hypophosphatemia (N = 1), anorexia (N = 1), asthenia (N = 1),
diarrhea (N = 1), abdominal pain (N = 1), dyspnea (N = 1), and
intolerance (N = 1). At the time of analysis, six patients were
still receiving treatment. Seven patients discontinued
everolimus for reasons other than disease progression
(infection [N = 2], patient refusal [N = 2], itching [N = 1], poor
PS [N = 1], and dyspnea [N = 1]).
Adverse events exceeding grade 3 were observed in 23
patients (46.9%). Anemia (10.2%), hyperglycemia (8.2%), and
infection (6.1%) were frequent complications experienced
during everolimus administration. Pneumonitis was observed
in three patients (6.1%) (grade 3 in two patients, grade 1 in
one patient).
discussion
Patients with nccRCC treated with everolimus showed an ORR
of 10.2% and a median PFS of 5.2 months. This seems
somewhat less efﬁcacious than the results of the ARCC trial, as
temsirolimus treatment led to a median PFS of 7.0 months in
nccRCC patients [16]. This discrepancy likely originates from
the difference in patient composition. In the ARCC trial, 75%
of nccRCC patients had papillary RCC, whereas in our trial,
<60% of patients had papillary RCC. Also, we did not exclude
sarcomatoid carcinoma and collecting duct carcinoma patients,
as we intended to determine the efﬁcacy of everolimus against
the different tumor histology subtypes. This is in contrast to
previous trials of targeted agents against nccRCC that usually
excluded collecting duct carcinoma and sarcomatoid
carcinoma in part due to the grave prognosis of these tumors
[17].
Patients with chromophobe RCC seemed to have longer PFS
than those with the other histological RCC subtypes examined
in this study. Additionally, 25% (2/8) of the chromophobe
RCC patients showed an objective tumor response to
everolimus. This is interesting because RCC patients do not
frequently show an objective tumor response to temsirolimus
and everolimus despite the considerably long PFS that both
drugs provide. In fact, the ORR after temsirolimus treatment
was 8.6% in the ARCC trial [7], and the ORR after everolimus
was 1% in the RECORD-1 trial [10]. Currently, little is known
about the tumor characteristics predictive of objective tumor
shrinkage after mTOR inhibitor treatment [18]. Notably,
research focused on Birt–Hogg–Dube syndrome revealed that
chromophobe RCC cells might have a genetic aberration in the
FLCN gene located on the short arm of chromosome 17 [19],
and FLCN−/− tumors have mTOR upregulation [20]. Hence,
chromophobe RCC may be a ‘real’ target of mTOR inhibitors.
More data from chromophobe RCC patients treated with an
mTOR inhibitor are needed to conﬁrm this assertion.
In this study, previous anti-VEGF treatment did not
inﬂuence the efﬁcacy of everolimus. However, prior treatment
with an anti-VEGF agent did seem to prolong the PFS of
nccRCC patients treated with everolimus (5.3 versus 3.7
months, Figure 2C). This ﬁnding is contrary to common
conjecture because it was previously found that antiangiogenic
therapy elicits the malignant progression of tumors [21]. To
explain this somewhat seemingly contradictory result, another
factor must be considered, the time from diagnosis to
everolimus administration. The time from diagnosis to targeted
therapy is a well-known prognostic factor, with longer time
from diagnosis to targeted therapy leading to a better
prognosis [22]. In our study, a long duration between diagnosis
and everolimus administration was a good prognostic factor
with strong statistical power. Interestingly, this time was
signiﬁcantly longer in patients with previous anti-VEGF
treatment than in patients without (3.1 versus 2.0 months,
P < 0.001). Also, in multivariate analysis of PFS considering
these two variables (anti-VEGF treatment and time from
Figure 1. Waterfall plot showing the maximal tumor shrinkage of target
lesions after everolimus administration in 49 patients.
Table 3. Correlation between clinicopathological factors and best
response to everolimus
Characteristics Partial
response
Stable
disease
Progressive
disease
P
Histology 0.670
Papillary 2 14 12
Chromophobe 2 4 1
Collecting duct 0 1 1
Sarcomatoid 0 2 1
Unclassiﬁable 1 4 1
Previous
immunotherapy
0.730
Yes 1 2 2
No 4 23 14
Previous anti-VEGF* 0.293
Yes 1 14 7
No 4 11 9
Nephrectomy 0.602
Yes 4 17 13
No 1 8 3
Risk group 0.281
Favorable 0 3 0
Intermediate 4 15 13
Poor 1 6 2
*Either sorafenib or sunitinib. VEGF, vascular endothelial growth factor.
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diagnosis to everolimus administration), only time from
diagnosis to everolimus administration was a signiﬁcant
independent factor for long PFS (P = 0.049, hazard ratio 0.692).
Hence, the tendency for patients previously treated with anti-
VEGF to have a long PFS after everolimus treatment in our
study is due to a confounding effect. Accordingly, in nccRCC
patients whose disease progressed while on anti-VEGF
treatment, subsequent treatment with mTOR inhibitors should
not be excluded.
Risk stratiﬁcation by the International mRCC DB
Consortium risk groups failed to show prognostic value in our
study. The original patient cohort from which the International
mRCC DB Consortium Risk Groups arose included only 35
nccRCC patients [15]. Hence, it is not surprising that this risk
stratiﬁcation system did not show a prognostic impact in our
study. We believe that veriﬁcation of the International mRCC
DB Consortium stratiﬁcation system in a greater number of
nccRCC patients is necessary to identify the clinical value of
this risk stratiﬁcation system. Because this risk stratiﬁcation
system showed prognostic value in a recent phase II trial of
sunitinib in 29 nccRCC patients [23], it might be inﬂuenced by
the type of targeted agent administered. Unfortunately, we
could not show any prognostic impact of the Memorial Sloan-
Figure 2. Progression-free survival (PFS) and overall survival (OS) of 49 patients (A, E), PFS according to tumor histology (B, F), PFS according to prior
anti-VEGF treatment (C, G), and PFS according to risk grouping (D, H).
Table 4. Efﬁcacy of everolimus according to tumor histology
Papillary Chromophobe Others*
ORR (%) 6.9 25 8.3
Median PFS (months) 3.4 13.1 3.4
Median OS (months) 10.9 21.6 19.8
*includes collecting duct, sarcomatoid, and unclassiﬁable RCC.
original articles Annals of Oncology
 | Koh et al. Volume 24 | No. 4 | April 2013
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on M
ay 14, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Kettering prognostic factors model [24] due to a lack of
information regarding lactate dehydrogenase in our study
population. In addition, it should be noticed that the
aforementioned subgroup analysis needs validation in a large-
scale prospective trial, because the number of patients in each
subgroup was not large enough to derive conﬁdent conclusion.
After comparing our results with those of the RECORD-1
study, we concluded that nccRCC patients might earn a clinical
beneﬁt similar to that experienced by ccRCC patients from
everolimus treatment. In the RECORD-1 study, median PFS
was 4.9 months, which is comparable to that of our patients
(5.2 months, or 5.3 months excluding collecting duct and
sarcomatoid RCC). Conversely, the ORR was higher (10.2%
overall or 11.6% excluding collecting duct and sarcomatoid
RCC) in our study than in the RECORD-1 study (1%). This is
in agreement with the result of a subsequent analysis of the
ARCC trial by Dutcher et al. [25], and we believe these
ﬁndings will be helpful for the future design of clinical trials
concerning nccRCC and the clinical treatment of nccRCC
patients.
Recently, Christian et al. presented data regarding the
efﬁcacy of everolimus in nccRCC patients at the ASCO-GU
2012 annual meeting [11]. Although these are not clinical trial
results, but instead those of an expanded access program, they
analyzed 75 nccRCC patients, a considerably large number.
Therefore, based on our ﬁndings, we believe a full analysis of
the REACT study with the patients grouped by tumor
histology will provide valuable information regarding the
treatment of nccRCC with everolimus. Also, a clinical trial
evaluating the efﬁcacy of everolimus (RAPTOR, http://
clinicaltrials.gov/ct2/show/NCT00688753), and sunitinib
(SUPAP, http://clinicaltrials.gov/ct2/show/NCT00541008) in
papillary RCC would provide an important information in the
treatment of papillary RCC.
In conclusion, everolimus shows considerable efﬁcacy against
nccRCC, and chromophobe RCC patients in particular may
beneﬁt from everolimus treatment. Also, previous treatment
with a VEGF-TKI appears to not inﬂuence the outcome of
everolimus therapy in nccRCC patients.
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